|Articles|December 6, 2022
Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply
Author(s)Eurofins
A panel of experts from bio/pharmaceutical companies discuss plasmids to establish specifications using a risk-based approach to manage supply, including the response to cell & gene therapy industry feedback, future outlook and re-evaluating plasmid risks.
Related Content
Trending on Pharmaceutical Technology
1
Why Oral Solid Dosage Validation Is a Business Continuity Function, Not Just a Compliance Requirement
2
European Regulators Prepare the Pharma Industry for Future Changes as Legislation is Formalized
3
Technology Transfer: Success Drivers and Obstacles Explained
4
Data Aggregation Drives AI's Impact on Clinical Supply Chains
5